<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tab1" orientation="portrait" position="float">
 <label>Table 1</label>
 <caption>
  <p>Malaysian herbal plants and their active constituents with potential therapeutic applications in sepsis.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left" rowspan="1" colspan="1">Scientific name (local name)</th>
    <th align="center" rowspan="1" colspan="1">Family</th>
    <th align="center" rowspan="1" colspan="1">Experimental model</th>
    <th align="center" rowspan="1" colspan="1">Type of sample (concentration or dose used)/mode and duration of treatment</th>
    <th align="center" rowspan="1" colspan="1">Antisepsis properties</th>
    <th align="center" rowspan="1" colspan="1">Positive drug control</th>
    <th align="center" rowspan="1" colspan="1">References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="7" colspan="1">
     <italic>Andrographis paniculata</italic> (hempedu bumi)
    </td>
    <td align="left" rowspan="7" colspan="1">Acanthaceae</td>
    <td align="left" rowspan="3" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Ethyl acetate extract (2–10 
     <italic>μ</italic>g/mL), pretreatment (1 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits NO and PGE
     <sub>2</sub> production
     <break/>(ii) Inhibits NF-
     <italic>κ</italic>B transcriptional activity in LPS-/IFN-
     <italic>γ</italic>-induced macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">Helenalin, NF-
     <italic>κ</italic>B inhibitor (10 
     <italic>μ</italic>M), pretreatment (1 hr)
    </td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B43" ref-type="bibr">43</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Ethyl acetate extract (2.5–20 
     <italic>μ</italic>g/mL), pretreatment (1 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Decreases NO, MIP-2, TNF-
     <italic>α</italic>, and IL-6 production in LPS-/IFN-
     <italic>γ</italic>-induced macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">Helenalin, NF-
     <italic>κ</italic>B inhibitor (10 
     <italic>μ</italic>M), pretreatment (1 hr)
    </td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B44" ref-type="bibr">44</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Andrographolide (1–10 
     <italic>μ</italic>M), posttreatment (6 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Reduces endothelial permeability
     <break/>(ii) Inhibits CAMs expression
     <break/>(iii) Suppresses monocyte adhesion and transmigration
     <break/> (iv) Inhibits TNF-
     <italic>α</italic> and IL-1
     <italic>β</italic> production in HMGB-1-induced HUVECs
    </td>
    <td align="left" rowspan="1" colspan="1">Emodin-6-O-
     <italic>β</italic>-D-glucoside (EG) (10 
     <italic>μ</italic>M), posttreatment (6 hr)
    </td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B45" ref-type="bibr">45</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="4" colspan="1">
     <italic>In vivo</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Ethyl acetate extract (0.78–3.12 mg/kg) via oral administration, daily for one week before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate
     <break/>(ii) Reduces serum levels of TNF-
     <italic>α</italic>, MIP-2, and NO in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">Pyrrolidine dithiocarbamate (PDTC), NF-
     <italic>κ</italic>B inhibitor (50 mg/kg) via intraperitoneal injection, 1 hr before LPS stimulation
    </td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B44" ref-type="bibr">44</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Andrographolide (3.5–7.0 
     <italic>μ</italic>g/mouse) via intravenous injection 16 hr after the CLP procedure
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits HMGB-1 production
     <break/>(ii) Decreases vascular permeability
     <break/>(iii) Suppresses leukocytes and neutrophils migration
     <break/>(iv) Improves survival rate in CLP-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">Emodin-6-O-
     <italic>β</italic>-D-glucoside (EG) (9.0 
     <italic>μ</italic>g/mouse) via intravenous injection 16 hr after the CLP procedure
    </td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B45" ref-type="bibr">45</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Andrographolide (1–10 mg/kg) via intraperitoneal injection 10 min after LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Attenuates ALI
     <break/>(ii) Reduces TNF-
     <italic>α</italic>, IL-1
     <italic>β</italic>, and IL-6 levels in BALF 
     <break/>(iii) Inhibits NF-
     <italic>κ</italic>B activation and its DNA binding activity in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B46" ref-type="bibr">46</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Andrographolide (2.5–10 mg/kg) via intraperitoneal injection 1 hr after LPS/D-galactosamine challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Attenuates acute liver injury
     <break/>(ii) Reduces serum levels of ALT and AST
     <break/>(iii) Inhibits hepatic TNF-
     <italic>α</italic> and IL-1
     <italic>β</italic> production 
     <break/>(iv) Inhibits NF-
     <italic>κ</italic>B activation in LPS-/D-galactosamine-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B47" ref-type="bibr">47</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="10" colspan="1">
     <italic>Zingiber officinale</italic> (halia)
    </td>
    <td align="left" rowspan="10" colspan="1">Zingiberaceae</td>
    <td align="left" rowspan="4" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Alcoholic ginger extract (1 
     <italic>μ</italic>l/mL), cotreatment (24 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits production of proinflammatory cytokines (IL-1
     <italic>β</italic>, IL-12, and TNF-
     <italic>α</italic>)
     <break/>(ii) Inhibits production of chemokines (RANTES and MCP-1) in LPS-induced macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B48" ref-type="bibr">48</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">6-Gingerol (1 
     <italic>μ</italic>g/mL), cotreatment (24 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits production of proinflammatory cytokines (IL-1
     <italic>β</italic>, IL-12, and TNF-
     <italic>α</italic>) 
     <break/>(ii) Inhibits production of chemokine (RANTES) in LPS-induced macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B49" ref-type="bibr">49</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Zingerone (10–50 
     <italic>μ</italic>M), posttreatment (6 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits endothelial hyperpermeability
     <break/>(ii) Suppresses expression of CAMs (ICAM and VCAM) 
     <break/>(iii) Reduces adhesion and migration of neutrophils in HMGB-1-induced HUVECs
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B50" ref-type="bibr">50</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Zingerone (10–50 
     <italic>μ</italic>M), posttreatment (6 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits endothelial hyperpermeability
     <break/>(ii) Suppresses expression of CAMs (ICAM and VCAM) 
     <break/>(iii) Reduces adhesion and migration of neutrophils in TGFBIp-induced HUVECs
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B51" ref-type="bibr">51</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="6" colspan="1">
     <italic>In vivo</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Dried ginger extract dissolved in distilled water (100–1000 mg/kg) via oral administration for 3 days before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Decreases IL-6 and IFN-
     <italic>γ</italic> production 
     <break/>(ii) Inhibits iNOS and COX-2 expression in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B52" ref-type="bibr">52</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">6-Gingerol (40 mg/kg) via intragastric administration for 5 days before the CLP procedure</td>
    <td align="left" rowspan="1" colspan="1">(i) Attenuates liver injury
     <break/>(ii) Decreases serum levels of ALT and AST 
     <break/>(iii) Reduces serum level of IL-1
     <italic>β</italic> in CLP-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B53" ref-type="bibr">53</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Zingerone (0.36 and 0.72 mg/kg) via intravenous injection 12 hr and 50 hr after the CLP procedure</td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate 
     <break/>(ii) Alleviates tissue injury (renal, hepatic, and pulmonary injury) in CLP-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B50" ref-type="bibr">50</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Zingerone (0.36 and 0.72 mg/kg) via intravenous injection 12 hr and 50 hr after TGFBIp injection</td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate
     <break/>(ii) Alleviates tissue injury (renal, hepatic, and pulmonary injury) in TGFBIp-induced CLP mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B51" ref-type="bibr">51</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Zingerone (10–40 mg/kg) via intragastric administration 1 hr before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Attenuates ALI 
     <break/>(ii) Reduces serum levels of TNF-
     <italic>α</italic> and IL-1
     <italic>β</italic> in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">Dexamethasone (5 mg/kg) via intragastric administration 1 hr before LPS challenge</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B54" ref-type="bibr">54</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Zingerone (10–40 mg/kg) via intraperitoneal injection 1 hr after LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Decreases serum levels of blood urea nitrogen (BUN) and creatinine
     <break/>(ii) Attenuates kidney injury 
     <break/>(iii) Reduces levels of IL-1
     <italic>β</italic>, IL-6, and TNF-
     <italic>α</italic> in the serum and kidney tissue in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">Viral inhibitory peptide for TLR4 (VIPER) (0.1 mg/kg) via intravenous injection 2 hr before LPS challenge</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B55" ref-type="bibr">55</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="10" colspan="1">
     <italic>Curcuma longa</italic> (kunyit)
    </td>
    <td align="left" rowspan="10" colspan="1">Zingiberaceae</td>
    <td align="left" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <italic>C. longa</italic> extract-loaded nanoemulsion (CLEN) (5 
     <italic>μ</italic>g/mL), cotreatment (24 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits NO production
     <break/>(ii) Suppresses HMGB-1 release 
     <break/>(iii) Inhibits iNOS expression in LPS-stimulated macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B56" ref-type="bibr">56</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="9" colspan="1">
     <italic>In vivo</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">CLEN (50 mg/kg) via intraperitoneal injection together with LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate in LPS-induced mice</td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B56" ref-type="bibr">56</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Curcumin (3.5 
     <italic>μ</italic>mol/kg) via intravenous injection 5 hr after the CLP procedure
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate
     <break/>(ii) Reduces levels of tissue injury markers (ALT, AST, and lactate) 
     <break/>(iii) Decreases TNF-
     <italic>α</italic> level in CLP-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B57" ref-type="bibr">57</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Curcumin (100 mg/kg) via intraperitoneal injection for 48 hr before the CLP procedure</td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate
     <break/>(ii) Attenuates blood-brain barrier dysfunction 
     <break/>(iii) Inhibits leukocytes and platelets adhesion in CLP-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B58" ref-type="bibr">58</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Curcumin (10 mg/kg) via intranasal administration 1 hr before LPS instillation</td>
    <td align="left" rowspan="1" colspan="1">(i) Attenuates ALI
     <break/>(ii) Decreases NO and TNF-
     <italic>α</italic> levels 
     <break/>(iii) Inhibits vascular leakage in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">Dexamethasone (5 mg/kg) via intraperitoneal injection 1 hr before LPS instillation</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B59" ref-type="bibr">59</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Curcumin (200 mg/kg) via intraperitoneal injection 30 min before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Attenuates ALI 
     <break/>(ii) Reduces TNF-
     <italic>α</italic>, IL-6, and MIP-2 levels in BALF in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B60" ref-type="bibr">60</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Curcumin (20–80 mg/kg) via oral administration daily for 4 weeks before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits production of proinflammatory cytokines (IL-1
     <italic>β</italic>, IL-6, and TNF-
     <italic>α</italic>) 
     <break/>(ii) Prevents liver failure in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B61" ref-type="bibr">61</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Curcumin (20 mg/kg) via intraperitoneal injection 1 hr before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate 
     <break/>(ii) Decreases the levels of TNF-
     <italic>α</italic> and inflammatory cells in BALF in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">Dexamethasone (1 mg/kg) via intraperitoneal injection 1 hr before LPS challenge</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B62" ref-type="bibr">62</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Curcumin (200 mg/kg/day) via intragastric administration for 3 days</td>
    <td align="left" rowspan="1" colspan="1">(i) Attenuates cardiac dysfunction in CLP-induced mice</td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B63" ref-type="bibr">63</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Curcumin (50–100 mg/kg) via intraperitoneal injection 3 hr before or after LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Improves vascular function
     <break/>(ii) Maintains normal heart rate 
     <break/>(iii) Restores normal arterial blood pressure in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B64" ref-type="bibr">64</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="7" colspan="1">
     <italic>Piper nigrum</italic> (lada hitam)
    </td>
    <td align="left" rowspan="7" colspan="1">Piperaceae</td>
    <td align="left" rowspan="3" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Ethanol extract (NA)</td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits NO production in LPS stimulated macrophages</td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B65" ref-type="bibr">65</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Piperine (20–80 
     <italic>μ</italic>M), pretreatment (4 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits IL-1
     <italic>β</italic> production 
     <break/>(ii) Inhibits HMGB-1 production in LPS-stimulated macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B66" ref-type="bibr">66</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Pellitorine (3–20 
     <italic>μ</italic>M), pretreatment (6 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Reduces endothelial permeability
     <break/>(ii) Inhibits CAMs expression 
     <break/>(iii) Suppresses leukocytes adhesion and migration in HMGB-1-induced HUVECs
    </td>
    <td align="left" rowspan="1" colspan="1">Emodin-6-O-
     <italic>β</italic>-D-glucoside (EG) (10 
     <italic>μ</italic>M), pretreatment (6 hr)
    </td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B67" ref-type="bibr">67</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="4" colspan="1">
     <italic>In vivo</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Piperine (1 and 5 mg/kg) via intraperitoneal injection 1 hr before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate
     <break/>(ii) Inhibits TNF-
     <italic>α</italic> production in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B68" ref-type="bibr">68</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Piperine (20 mg/kg) via intragastric administration for 5 days before 
     <italic>E. coli</italic> injection
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Reduces serum and BALF levels of IL-1
     <italic>β</italic>
     <break/>(ii) Reduces pro-IL-1
     <italic>β</italic> and IL-1
     <italic>β</italic> protein levels in colonic tissue in 
     <italic>E. coli</italic>-infected mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B66" ref-type="bibr">66</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Piperine (15–60 mg/kg) via intraperitoneal injection 1 hr after LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Attenuates ALI
     <break/>(ii) Reduces IL-1
     <italic>β</italic>, IL-6, and TNF-
     <italic>α</italic> levels in BALF 
     <break/>(iii) Inhibits NF-
     <italic>κ</italic>B activation in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B69" ref-type="bibr">69</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Pellitorine (4.5–9.0 
     <italic>μ</italic>g/mouse) via intravenous injection 6 hr before HMGB-1 challenge
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate
     <break/>(ii) Reduces vascular permeability
     <break/>(iii) Inhibits CAMs expression
     <break/>(iv) Inhibits leukocytes adhesion and migration in HMGB-1-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">Emodin-6-O-
     <italic>β</italic>-D-glucoside (EG) (9.0 
     <italic>μ</italic>g/mouse) via intravenous injection 6 hr before HMGB-1 challenge
    </td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B67" ref-type="bibr">67</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="5" colspan="1">
     <italic>Syzygium aromaticum</italic> (bunga cengkih)
    </td>
    <td align="left" rowspan="5" colspan="1">Myrtaceae</td>
    <td align="left" rowspan="3" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Methanol extract (10 
     <italic>μ</italic>g/mL), cotreatment (9–24 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits PGE
     <sub>2</sub> production in LPS-induced macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B70" ref-type="bibr">70</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Methanol extract (100 
     <italic>μ</italic>g/well), pretreatment (2 hr) and posttreatment (22 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits IL-1
     <italic>β</italic>, IL-6, and IL-10 production in LPS-induced macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">Dexamethasone (100 
     <italic>μ</italic>M)
    </td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B71" ref-type="bibr">71</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Biflorin (15–60 
     <italic>μ</italic>M), pretreatment (1 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits NO, PGE
     <sub>2</sub>, IL-6, and TNF-
     <italic>α</italic> production
     <break/>(ii) Inhibits iNOS and COX-2 expression in LPS-stimulated macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">L-NIL (20 
     <italic>μ</italic>M) and NS-398 (3 
     <italic>μ</italic>M), pretreatment (1 hr)
    </td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B72" ref-type="bibr">72</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="2" colspan="1">
     <italic>In vivo</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Aqueous extract (200 mg/kg) via intraperitoneal injection for 2 days before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits lung inflammation in LPS-induced mice</td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B73" ref-type="bibr">73</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Biflorin (5 and 10 mg/kg) via intraperitoneal injection 1 hr before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate
     <break/>(ii) Reduces TNF-
     <italic>α</italic> production
     <break/>(iii) Inhibits iNOS and COX-2 expression in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B72" ref-type="bibr">72</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="5" colspan="1">
     <italic>Momordica charantia</italic> (peria)
    </td>
    <td align="left" rowspan="5" colspan="1">Cucurbitaceae</td>
    <td align="left" rowspan="4" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Hot water (500–2000 
     <italic>μ</italic>g/mL), ethanol (12.5–50 
     <italic>μ</italic>g/mL), and ethyl acetate (25–100 
     <italic>μ</italic>g/mL) extracts, cotreatment (6–24 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits NO and PGE
     <sub>2</sub> production 
     <break/>(ii) Inhibits iNOS and pro-IL-1
     <italic>β</italic> expression in LPS-stimulated macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">Gentisic acid (1 mM), cotreatment (18–24 hr)</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B74" ref-type="bibr">74</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Methanol extract (100–200 
     <italic>μ</italic>g/mL), pretreatment (30 min)
    </td>
    <td align="left" rowspan="2" colspan="1">(i) Inhibits NO and PGE
     <sub>2</sub> production
     <break/>(ii) Inhibits iNOS and COX-2 expression in LPS-induced macrophages
     <break/>(i) Inhibits PGE
     <sub>2</sub> production in LPS-induced macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">L-NAME (1–1.5 mM) and indomethacin (0.5–5 
     <italic>μ</italic>M), pretreatment (30 min)
    </td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B75" ref-type="bibr">75</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Water extract (0.01–0.5 mg/mL), cotreatment (12–18 hr)</td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B76" ref-type="bibr">76</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Ethanol, ethyl acetate, petroleum ether, and aqueous extracts (0.1 mg/mL), pretreatment (12 hr)</td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits NO production in LPS-stimulated macrophages</td>
    <td align="left" rowspan="1" colspan="1">Ibuprofen (0.1 mg/mL), pretreatment (12 hr)</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B77" ref-type="bibr">77</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <italic>In vivo</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Lyophilized powder (1%–10% (w/w)) in food pellets daily for 4 weeks before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Reduces serum levels of proinflammatory cytokines (TNF-
     <italic>α</italic>, IL-1
     <italic>β</italic>, and IL-6) and increases serum level of anti-inflammatory cytokine (IL-10)
     <break/>(ii) Inhibits expression of NF-
     <italic>κ</italic>B, iNOS, and COX-2 
     <break/>(iii) Diminishes liver injury biomarkers (ALT, AST, and C-RP) in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">Pyrrolidine dithiocarbamic acid ammonium salt (PDTC) (50 mg/kg) via intravenous injection 1 hr before LPS challenge</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B78" ref-type="bibr">78</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="12" colspan="1">
     <italic>Centella asiatica</italic> (pegaga)
    </td>
    <td align="left" rowspan="12" colspan="1">Apiaceae</td>
    <td align="left" rowspan="3" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Ethanol extract (3.91–1000 
     <italic>μ</italic>g/mL), posttreatment (24 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits NO, TNF-
     <italic>α</italic>, and PGE2 production in LPS-induced macrophages
    </td>
    <td align="left" rowspan="1" colspan="1">Dexamethasone (5 
     <italic>μ</italic>M), posttreatment (24 hr)
    </td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B79" ref-type="bibr">79</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="2" colspan="1">Asiatic acid (10–40 
     <italic>μ</italic>M), cotreatment (48 hr)
    </td>
    <td align="left" rowspan="1" colspan="1">(i) Inhibits NO, IL-1
     <italic>β</italic>, and IL-6 production
    </td>
    <td align="left" rowspan="2" colspan="1">NA</td>
    <td align="center" rowspan="2" colspan="1">[
     <xref rid="B80" ref-type="bibr">80</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">(ii) Inhibits NF-
     <italic>κ</italic>B activation in LPS-induced macrophages
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="9" colspan="1">
     <italic>In vivo</italic>
    </td>
    <td align="left" rowspan="1" colspan="1">Ethanol extract (300 and 350 mg/kg) via oral administration after LPS challenge for 11 days</td>
    <td align="left" rowspan="1" colspan="1">(i) Reduces serum levels of TNF-
     <italic>α</italic> and PGE2 in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">Rivastigmine (5 mg/kg) via oral administration after LPS challenge for 11 days</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B79" ref-type="bibr">79</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Asiaticoside (45 mg/kg) via intraperitoneal injection 1 hr before the CLP procedure</td>
    <td align="left" rowspan="1" colspan="1">(i) Attenuates ALI
     <break/>(ii) Reduces serum levels of IL-6 and TNF-
     <italic>α</italic>
     <break/>(iii) Inhibits COX-2 and iNOS expression in lung tissue 
     <break/>(iv) Inhibits NF-
     <italic>κ</italic>B activation in CLP-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B81" ref-type="bibr">81</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Asiaticoside (15–45 mg/kg) via intraperitoneal injection 1 hr before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Attenuates ALI
     <break/>(ii) Reduces IL-6 and TNF-
     <italic>α</italic> levels in BALF 
     <break/>(iii) Inhibits NF-
     <italic>κ</italic>B activation in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B82" ref-type="bibr">82</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Asiaticoside (10 and 20 mg/kg) via oral administration for 3 days before the LPS/D-galactosamine challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate
     <break/>(ii) Attenuates liver injury
     <break/>(iii) Reduces serum levels of ALT and AST
     <break/>(iv) Decreases TNF-
     <italic>α</italic> level in serum and hepatic tissue in LPS-/D-galactosamine-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">Silymarin (50 mg/kg) via oral administration for 3 days before LPS/D-galactosamine challenge</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B83" ref-type="bibr">83</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Asiaticoside (3–30 mg/kg) via oral administration at 24 hr before the LPS challenge and every 8 hr thereafter</td>
    <td align="left" rowspan="1" colspan="1">(i) Reduces serum levels of IL-1
     <italic>β</italic>, IL-6, and TNF-
     <italic>α</italic>
     <break/>(ii) Attenuates liver injury in LPS-treated rats
    </td>
    <td align="left" rowspan="1" colspan="1">Indomethacin (10 mg/kg) via oral administration at 24 hr before LPS challenge and every 8 hr thereafter</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B84" ref-type="bibr">84</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Asiatic acid (25–100 mg/kg) via intranasal administration 1 hr after LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Attenuates ALI
     <break/>(ii) Reduces IL-1
     <italic>β</italic>, IL-6, and TNF-
     <italic>α</italic> levels in BALF 
     <break/>(iii) Inhibits NF-
     <italic>κ</italic>B activation in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B85" ref-type="bibr">85</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Asiatic acid (10 and 30 mg/kg) via oral administration for 3 days before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Improves survival rate
     <break/>(ii) Attenuates organ (lung, liver, and kidney) damage 
     <break/>(iii) Decreases serum levels of IL-1
     <italic>β</italic>, IL-6, ALT, and BUN in LPS-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B80" ref-type="bibr">80</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Madecassoside (20 mg/kg) via intragastric administration for 5 days before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Prevents myocardial dysfunction
     <break/>(ii) Delays the drop in blood pressure 
     <break/>(iii) Attenuates tachycardia in LPS-treated rats
    </td>
    <td align="left" rowspan="1" colspan="1">NA</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B86" ref-type="bibr">86</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Madecassoside (20 and 40 mg/kg) via oral administration for 10 days before LPS challenge</td>
    <td align="left" rowspan="1" colspan="1">(i) Prevents acute liver failure
     <break/>(ii) Reduces serum levels of ALT and AST
     <break/>(iii) Inhibits IL-1
     <italic>β</italic>, IL-6, and TNF-
     <italic>α</italic> production in liver tissue 
     <break/>(iv) Inhibits iNOS and COX-2 expression in LPS-/D-galactosamine-induced mice
    </td>
    <td align="left" rowspan="1" colspan="1">Silibinin (100 mg/kg) via oral administration for 10 days before LPS challenge</td>
    <td align="center" rowspan="1" colspan="1">[
     <xref rid="B87" ref-type="bibr">87</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
